PPBT
Purple BiotechPPBT
PPBT
About: Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
Employees: 20
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
10% more capital invested
Capital invested by funds: $859K [Q2] → $946K (+$87.6K) [Q3]
0.71% less ownership
Funds ownership: 0.76% [Q2] → 0.05% (-0.71%) [Q3]
52% less funds holding
Funds holding: 21 [Q2] → 10 (-11) [Q3]
85% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 13
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 8
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$33
851%
upside
Avg. target
$33
851%
upside
High target
$33
851%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 16% 1-year accuracy 24 / 150 met price target | 851%upside $33 | Buy Reiterated | 15 Nov 2024 |
Financial journalist opinion
Based on 4 articles about PPBT published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering of 472,668 of the Company's American Depositary Shares (“ADSs”), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS.
Positive
Zacks Investment Research
2 weeks ago
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
Purple Biotech stock surges 150.4% on reporting superior efficacy data from the mid-stage study of its combo therapy on pancreatic cancer patients.
Neutral
GlobeNewsWire
2 weeks ago
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 472,668 of the Company's American Depositary Shares (“ADSs”), each ADS representing 200 ordinary shares, at a purchase price of $6.00 per ADS, in a registered direct offering. The closing of the offering is expected to occur on or about December 4, 2024, subject to the satisfaction of customary closing conditions.
Positive
Benzinga
3 weeks ago
Why Is Purple Biotech Stock Trading Higher On Monday?
On Monday, Purple Biotech Ltd PPBT reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma (PDAC).
Neutral
GlobeNewsWire
1 month ago
Purple Biotech Reports Third Quarter 2024 Financial Results
Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets CAPTN-3 tri-specific antibody platform data presented at the ENA Symposium October 2024 REHOVOT, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced financial results for the three and nine months ended September 30, 2024.
Neutral
GlobeNewsWire
1 month ago
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24
Neutral
GlobeNewsWire
1 month ago
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 demonstrates s ustained tumor regression in a triple negative breast cancer in-vivo model ; A dose dependent ac tivity and a synergistic effect of the engage r arm s also seen in non-small cell lung cancer patient-derived explants
Neutral
GlobeNewsWire
2 months ago
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer
Neutral
GlobeNewsWire
3 months ago
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
REHOVOT, Israel, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today reported new positive biomarker findings for its lead oncology therapeutic candidate CM24. These data were presented yesterday at the American Association for Cancer Research® (AACR) Special Conference on Advances in Pancreatic Cancer Research currently ongoing in Boston, in a poster titled, “Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer”.
Neutral
GlobeNewsWire
3 months ago
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
REHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced its executive management will participate in the H.C. Wainwright 26th Annual Global Investment Conference in a Fireside Chat presentation (virtual) and one-on-one meetings.
Charts implemented using Lightweight Charts™